Acumen: ACU193 Is A Promising Phase 1 Alzheimer’s Candidate, But Not More Than That
selvanegra Thesis Acumen (NASDAQ:ABOS) is a biotech company with one Phase 1 asset, ACU193, an amyloid oligomer targeting antibody. In bringing this drug candidate to trials, Acumen is essentially trying to validate not the amyloid […]
